Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
ConditionGlabellar Lines
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age19-65
SponsorDaewoong Pharmaceutical Co. LTD.
About this trial
To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- DWP712 inj.
- Botox® 100 Units
Treatment groups
324 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov